Slavinorm: critical limb-ischemia method — RU2827088C1
Евгений Петрович Кривощеков, Владислав Павлович Компаниец, Владислав Евгеньевич Романов, Николай Александрович Лысов, Максим Вячеславович Яшков, Дмитрий Валерьевич Роднянский · 2024 · RU2827088C1 · patent family RU2827088C1
Published 2024-09-23.
Reported patent results
Reported findings
Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.
Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Case 1: walking and ankle–brachial index | Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70 | Before versus after surgery and multidrug care · 5 months |
| Case 2: walking and ankle–brachial index | Walking distance reported as 800 m; affected-leg ABI increased from 0.27 to 0.80 | Before versus after combined care · 4 months |
| Case 2: later deterioration | Bypass thrombosis; walking distance fell to 300 m, without reported critical ischemia | Earlier 800 m result was not fully maintained · 1 year |
Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This 2024 method patent includes Slavinorm during combined treatment of critical limb ischemia in diabetes.
The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.
- Publication
- RU2827088C1 ↗ · 2024-09-23
- Earliest priority / filing
- Not established / 2024-03-20
- Original applicant / assignee
- Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for combined treatment of patients with critical ischemia of lower extremities with underlying diabetes mellitus
Inventors: Евгений Петрович Кривощеков; Владислав Павлович Компаниец; Владислав Евгеньевич Романов; Николай Александрович Лысов; Максим Вячеславович Яшков; Дмитрий Валерьевич Роднянский.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.
- Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2827088C1. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Евгений Петрович Кривощеков, Владислав Павлович Компаниец, Владислав Евгеньевич Романов, Николай Александрович Лысов, Максим Вячеславович Яшков, Дмитрий Валерьевич Роднянский. Slavinorm: critical limb-ischemia method — RU2827088C1 RU2827088C1 · patent family RU2827088C1 2024.
Molekul research summary: https://molekul.io/research/patent-ru2827088c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry